Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive loss of cognitive functions. Today the diagnosis of AD relies on clinical evaluations and is only late in the disease. Biomarkers for early detection of the underlying neuropathological changes are still lacking and the biochemical pathways leading to the disease are still not completely understood. The aim of this study was to identify the metabolic changes resulting from the disease phenotype by a thorough and systematic metabolite profiling approach. For this purpose CSF samples from 79 AD patients and 51 healthy controls were analyzed by gas and liquid chromatography-tandem mass spectrometry (GC-MS and LC-MS/MS) in conjunction with univariate and multivariate statistical analyses. In total 343 different analytes have been identified. Significant changes in the metabolite profile of AD patients compared to healthy controls have been identified. Increased cortisol levels seemed to be related to the progression of AD and have been detected in more severe forms of AD. Increased cysteine associated with decreased uridine was the best paired combination to identify light AD (MMSE>22) with specificity and sensitivity above 75%. In this group of patients, sensitivity and specificity above 80% were obtained for several combinations of three to five metabolites, including cortisol and various amino acids, in addition to cysteine and uridine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 1×
“Two main brain cortical lesions characterize AD: the accumulation of abnormally phosphorylated tau protein into paired helical filaments, known as neurofibrillary tangles (NFTs) within the neuronal cell and accumulation of beta amyloid outside the neurons in form of amyloid plaques and in the wall of cerebral blood ve…”
BackgroundCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“Indeed, there have been numerous studies (reviewed in [36] [37] using novel proteomics approaches that include not only unbiased analysis of CSF using protein separation techniques and mass spectroscopy, but also targeted approaches with multiplex panels of specific analytes.”
BackgroundSelf-citationSmith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., Oulhaj, A., Bradley, K. M., Jacoby, R., & Refsum, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012244 · Cited by 813 · cited 1×
“One clinical study has shown that lowering of homocysteine in plasma by Vitamin B12 slows the rate of brain atrophy, however without effect on cognitive parameters [35].”
Background
Cited by
Iturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain
Mather, M., & Harley, C. W. (2016) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2016.01.001 · Cited by 492
Trushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M., & Petersen, R. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063644 · Cited by 438
“Disorder in the hypothalamic-pituitary-adrenal (HPA) axis with increased cortisol levels in CSF and plasma is also well established for AD patients; and increased cortisol levels in CSF from AD patients have been recently demonstrated using metabolomic profiling [30].”
BackgroundResultInfluentialAmino acid catabolism in Alzheimer’s disease brain: Friend or foe?
Griffin, J. W. D., & Bradshaw, P. C. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/5472792 · Cited by 185
“One study found increased cysteine levels in CSF from AD subjects [28], while another one identified altered tryptophan and phenylalanine levels in plasma from bothMCI and AD subjects compared to controls; tryptophan levels were also distinct when comparingMCI to AD subjects [35].”
BackgroundResultInfluentialHampel, H., O’Bryant, S. E., Durrleman, S., Younesi, E., Rojkova, K., Escott-Price, V., Corvol, J.-C., Broich, K., Dubois, B., Lista, S., et al. (2017) · Climacteric · doi:10.1080/13697137.2017.1287866 · Cited by 147
Self-citationGonzález‐Domínguez, R., García, A., García‐Barrera, T., Barbas, C., & Gómez‐Ariza, J. L. (2014) · ELECTROPHORESIS · doi:10.1002/elps.201400196 · Cited by 119
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Self-citationHurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34
Metadata
- Authors
- Czech, C., Berndt, P., Busch, K., Schmitz, O., Wiemer, J., Most, V., Hampel, H., Kastler, J., & Senn, H.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-02-16
- Volume
- 7
- Issue
- 2
- Pages
- e31501
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2007466714
- Cited by
- 170
- References
- 4
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.